DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT00572689

WithdrawnPhase 4

Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

Asset

Exenatide

Subcutaneous · GLP-1 agonist

Listed sites

2

Recruiting sites

—

Enrollment

—

actual

Study population

Gestational diabetes

Key I/E criterion

•Female

Primary endpoint

•Glycemic control through insulin, glucose, c-peptide and glucagon assays

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00572689
Org study IDExenatide.GDM
Secondary ID202-801-2636

Timeline

Milestones

Study first posted2007-12-13estimated
Last update posted2015-08-21estimated
Study start2013-08 (month precision)
Primary completion2015-08actual (month precision)
Study completion2015-08actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Gestational diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age50 Years
SexFemale
Healthy volunteersNot accepted

Inclusion criteria

•Pregnant women (singleton)
•Gestational diabetes not requiring medical therapy
•Between 18 and 50 years of age
•Able to give written informed consent

Exclusion criteria

•Women in the first trimester of pregnancy
•Hematocrit less than 30%
•Current or past treatment with any hypoglycemic agent
•Women with gastrointestinal disease or symptoms consistent with nausea, vomiting, abdominal pain or reflux requiring medical treatment.
•Women with high triglyceride levels, history of gallbladder or pancreatic disease.
•Clinical diagnosis or history of any renal insufficiency (or decreased creatinine clearance)

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
1
Safety / tolerability / PK
1
Other (unclassified)
1

Glycemic / diabetes

1 endpoint
Primary/protocol endpoint/low confidence

glycemic control through insulin, glucose, c-peptide and glucagon assays

Time frame:duing testing days

descriptive, improvement

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Exenatide Pharmacodynamics and Pharmacokinetics

Time frame:During testing days

descriptive

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

TCF7L2 polymorphism

Time frame:During subject testing days

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.